CRISPR/Cas System for Treatment of Blood Disorders:
From Patent Landscape to Market Reality

This report offers an in-depth, data-backed analysis of CRISPR/Cas-based treatment of blood disorders, covering the patent landscape, assignee positioning, technology fragmentation, market structure, key players and strategic outlook, built for teams that need more than a surface-level overview to make informed decisions.

🔓 Unlock the Long Report · $1,500 See what's inside

One-time payment · Instant PDF access · No subscription

1,682

Global active IP families analysed

193

Granted patents identified in the domain

37.1%

Of IP assets concentrated in CN, EP & US

$13.39B

Projected CRISPR gene editing market by 2034

Short report vs. Long report

You've read the summary. Here's what it left out.

The short report offers the headline narrative. The long report delivers the underlying analysis, assignee-level intelligence, technology fragmentation, and complete market and legal context, that patent attorneys, R&D leaders and investors rely on to brief clients or leadership.

What you get

Short Report

Long Report

Contextual overview & executive synthesis

✓

Filing, prosecution & jurisdictional analytics

✓

Assignee intelligence: rankings, filing velocity & geographic footprint

✓

Technology fragmentation & node-level filing trends

✓

Market sizing, forecast & competitive product landscape

Overview only

✓ Full landscape

Corporate activity: M&A, licensing, ventures & academic alliances

✓

Litigation exposure & technology whitespace strategy

✓

Methodology, definitions & reference appendix

✓

The numbers shaping CRISPR-based blood disorder treatment

A sample of the findings inside the long report, each backed by sourced, citable data your team can put directly into a memo.

1,682

Patent Families Mapped

The report maps ~1,682 active INPADOC patent families in CRISPR/Cas system-based treatment of blood disorders, with more than 90% filed after 2016.

37.1%

CN, EP & US Dominate

China, Europe and the US together account for 37.1% of IP assets (624 patents), with 36.8% of filings routed through the PCT (WIPO) system.

~19%

Low Grant Rate

Average grants per year run at roughly 19% of average annual filings, pointing to a rapidly developing and still-maturing gene-editing IP landscape.

Broad Institute Leads

Broad Institute Inc (69), Massachusetts Institute of Technology (55) and Harvard Univ (55) top the assignee league table, closely followed by Editas Medicine and CRISPR Therapeutics.

1st

CASGEVY™ Sets the Bar

CASGEVY™ is the first and only approved medicine using CRISPR/Cas9 gene editing for blood disorders, with several other clinical trials underway across multiple phases.

$13.39B

Market to Nearly Triple

The global CRISPR-based gene editing market is projected to grow from $4.46 billion in 2025 to approximately $13.39 billion by 2034, a 13% CAGR.

Who this report is built for

Designed for Decision-Makers

Patent Attorneys & IP Counsel

Freedom-to-operate context and assignee-level filing intelligence for client advisory on CRISPR-based blood therapies.

Bio

Gene-Therapy & R&D Leaders

Technology-maturity benchmarking to prioritise where CRISPR delivery and editing approaches move the needle next.

Investors & Analysts

Reconciled market models and named-company positioning for diligence and thesis-building in gene-editing therapeutics.

Business Development & Licensing Teams

A board-ready narrative on where to file, partner, or license as blood-disorder therapies push toward broader approval.

CRISPR/Cas System for Treatment of Blood Disorders: Long Report

Full PDF report · Delivered instantly to your inbox

~1,682 active INPADOC patent families mapped across CRISPR/Cas system-based treatment of blood disorders
Detailed patent filing, grant and jurisdictional analysis, including PCT filing routes
Top patent holders and assignee-level competitive intelligence, with year-by-year filing trends
Assignee-wise geographical footprint across China, Europe, the US, Japan and Australia
Detailed technology taxonomy covering CRISPR systems, methods of delivery, blood disorders and dosage forms
Filing trends broken down node by node across the technology taxonomy
Market size and forecast analysis for CRISPR-based gene editing in blood disorder treatment
Key market players and their pipeline products, including CASGEVY™ and multiple clinical-trial assets
Mergers & acquisitions, university collaborations, joint ventures and key licensing deals
Litigation tracking across the CRISPR gene-editing space
Technology whitespaces, potential opportunities, risks and actionable insights
Taxonomy definitions, inclusions and exclusions, and a full country table appendix

🔒 Secure checkout

⚡ Instant delivery

🧾 Invoice available

🔒 Encrypted payment · Processed securely

Frequently Asked Questions

How is this different from the short report on the website?

The short report is a focused summary. The long report adds the assignee-based trends (top holders, filing trend, geographical footprint), the full technology fragmentation breakdown, a much deeper market section covering forecasts, current market sizing, M&A, university collaborations, joint ventures, licensing deals and litigation, plus the taxonomy definitions appendix, the material teams actually cite in memos and board decks.

What format is the report delivered in?

A full PDF report, delivered instantly to the email used at checkout, along with a companion chart pack for internal presentations.

Is the data sourced and citable?

Yes. Every figure is drawn from Intelacia’s original patent analysis and cross-referenced against major market-research houses, with sourcing notes included in the report.

CRISPR/Cas System for Treatment of Blood Disorders:From Patent Landscape to Market Reality